AbbVie Collaborates with Sosei Heptares to Develop Small Molecules for Neurological Conditions
By Ashish Tripathi
Pharma Deals Review: Vol 2022 Issue 8 (Table of Contents)
Published: 12 Aug-2022
DOI: 10.3833/pdr.v2022.i8.2714 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a bid to bolster its pipeline, AbbVie has partnered with Sosei Heptares to develop and commercialise small molecules that modulate new G protein-coupled receptor (GPCR) targets associated with neurological disease...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS